Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical (Nasdaq: COLL) announced eight poster presentations at PAINWeek Conference 2024, showcasing data on its diversified pain portfolio. The posters, available from September 4-6, 2024, cover topics such as healthcare costs, treatment characteristics, safety, and nonmedical use of various pain medications including Belbuca®, Xtampza® ER, and Nucynta®.
The presentations highlight real-world data and clinical insights on Collegium's pain management products, demonstrating their impact on patient care and population health. The company emphasizes its commitment to responsible pain management and advancing its mission to improve the lives of people with serious medical conditions.
Collegium Pharmaceutical (COLL) reported strong Q2 2024 financial results, with net revenue of $145.3 million, up 7% year-over-year. Belbuca achieved record revenue of $52.2 million, a 21% increase. GAAP net income rose 51% to $19.6 million, while adjusted EBITDA grew 12% to $96.0 million. The company reaffirmed its full-year 2024 guidance and is on track to close the acquisition of Ironshore Therapeutics in Q3, adding Jornay PM to its portfolio and expanding into the ADHD market. Collegium also secured a new $646 million term loan, reducing its cost of capital by 300 basis points.
Collegium Pharmaceutical (Nasdaq: COLL) has announced a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash, with a potential additional $25 million commercial milestone payment. This acquisition will expand Collegium's portfolio into neurology, specifically the ADHD market, through Ironshore's product Jornay PM. Key highlights include:
- Jornay PM's H1'24 prescriptions grew 32% year-over-year
- The transaction is expected to be immediately accretive to adjusted EBITDA
- Acquisition funded by cash on hand and new five-year financing
- Collegium estimates Q2'24 Pain Portfolio Net Revenue of $145 million, up 7% year-over-year
- The deal is expected to close in Q3 2024, subject to regulatory approvals
This strategic move aligns with Collegium's mission to build a diversified specialty pharmaceutical company, leveraging its commercial capabilities in a new market.
Collegium Pharmaceutical (Nasdaq: COLL), a diversified specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the release. Investors can access the call by dialing (877) 407-8037 (U.S.) or (201) 689-8037 (International) and referencing the "Collegium Pharmaceutical Q2 2024 Earnings Call." An audio webcast will be available on the company's website, with a replay accessible approximately two hours after the event.
Collegium Pharmaceutical has announced that the FDA has granted a six-month pediatric exclusivity extension for its Nucynta Franchise. This extension extends Nucynta's exclusivity to January 3, 2027, and Nucynta ER's exclusivity to December 27, 2025. The FDA had previously granted New Patient Population exclusivity for Nucynta in pediatrics, extending it until July 3, 2026. This extension is seen as a value enhancement for the Nucynta franchise, which is used for managing severe acute and persistent pain in both adults and pediatric patients. Collegium's Chief Medical Officer, Thomas Smith, highlighted the significance of this development for the company's near-term outlook and commitment to supporting patients with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the Jefferies Global Healthcare Conference in New York, NY, on June 5-6, 2024. The company's management will engage in a fireside chat on June 5, 2024, at 9:30 a.m. ET. The event will be webcast live and available on Collegium's Investors section. Additionally, a replay of the webcast will be accessible for 90 days post-event.
Collegium Pharmaceutical, Inc. announced a $35 million Accelerated Share Repurchase (ASR) program with Jefferies to buy back common stock as part of a $150 million repurchase program. The company aims to enhance shareholder value by leveraging its capital deployment strategy. The ASR agreement will result in Collegium receiving 888,889 shares initially, with the final number based on stock prices during the term.
Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.
Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
